@article {8222,
	title = {Treatment of waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine},
	journal = {Annals of Internal Medicine},
	volume = {118},
	year = {1993},
	note = {Cited By :103Export Date: 21 February 2017},
	month = {1993},
	pages = {195 - 198},
	abstract = {Objective: To evaluate the activity of 2-chlorodeoxyadenosine (2CdA) in the treatment of patients with Waldenstrom macroglobulinemia. ■ Design: Uncontrolled phase II trial. ■ Setting: Tertiary, referral cancer center. ■ Patients: Twenty-nine consecutive, symptomatic patients with Waldenstrom macroglobulinemia, of whom 9 were previously untreated. ■ Intervention: 2-Chlorodeoxyadenosine was administered as a continuous intravenous infusion at a dose of 0.1 mg/kg body weight per day for 7 days. Only two courses of 2CdA were given and responding patients were then followed without further treatment. ■ Measurements and Main Results: A total of 17 (59\%) patients responded, including all of those who were newly diagnosed and 40\% of those who had failed previous therapies. Treatment was well tolerated except for one death in a patient who had presented with severe pancytopenia. With a median follow-up of 7 months, only one responding patient has relapsed. ■ Conclusion: 2-Chlorodeoxyadenosine is a nucleoside analog that was effective in most patients with Waldenstrom macroglobulinemia and was associated with little toxicity.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-0027492159\&partnerID=40\&md5=883b46b005e5fe2f4fd6f000555938c7},
	author = {Dimopoulos, M.A. and Kantarjian, H. and Estey, E. and O{\textquoteright}Brien, S. and Delasalle, K. and Keating, M.J. and Freireich, E.J. and Alexanian, R.}
}
